Life Sciences & Chemistry

Start-up = challenge? Let’s tackle it together! 

Are you a founder in the field of life science and chemistry and on the lookout for financing? At HTGF, we not only offer you investment know-how, but also understand your specific needs and provide you with the right expertise to support your business ideas. We leverage our tailored network to help you achieve success.

Our Life Sciences & Chemistry team has the required start-up spirit! We have both entrepreneurial expertise and an understanding of science, medicine and practical applications. Having invested in over 200 life science and chemical companies since 2005, we know what really matters.

With our expertise and passion, we are at your side as a sparring partner from seed to exit – whether it be in the field of drug development and biotech, medtech and diagnostics, digital health, R&D tools or chemistry.

 Many steps must be taken to become a successful start-up

The right tools

We offer you the right tools to meet your individual challenges as a founder of a life sciences and chemical start-up:

We help you get started

  • Fast and flexible seed financing
  • Matching with co-investors from our international network
  • Communication on an equal footing
  • Inspiration and knowledge transfer

Let’s develop and grow together

  • Support in the acquisition of follow-up financing
  • Exchanges with founders and our partners from research, industry and SMEs
  • Close connection with cooperation partners

A shared path – from seed to exit

  • Support in finding the most suitable M&A advisors
  • Support in negotiations and due diligence
  • Assistance with company valuations and incentives
  • Transaction security from trade sale to IPO
  • Access to the HTGF network with many potential buyers

Who we are

What you can expect from us

  • From the very early stage to the exit, we support you as partners with our know-how and understanding of your needs.
  • We have an entrepreneurial spirit – many of us have founded our own companies and we have the necessary appetite for risk
  • We understand how financing works and can call on our network
  • We have backgrounds as scientists and know the pitfalls: manufacturing/CMC, regulatory affairs, market access, team growth, business development, etc.

The areas we invest in include:

  Pharma/biotech

  Medtech

  R&D tools

  Diagnostics

  Digital health

  Chemistry

Our Life Sciences & Chemistry Portfolio 

Let’s turn ideas into reality!

Societal challenges, such as diseases or advancing climate change, require innovative solutions. And this is why pioneering start-ups in the fields of life sciences and healthcare, chemistry, food and agricultural technology, and new materials are playing a crucial role.

Germany has the platform to continue launching successful high-tech start-ups:

  • Top-class research at universities and institutes
  • Close cooperation between industry and consumers
  • Transfer-enabling support

With your innovative start-up ideas, we can create sustainable and disruptive solutions together – what are we waiting for?

Looking to start a business? Contact our team here.

Is your pitch deck complete? Upload it here!

Topics that might interest you

Press
3. May 2022

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

MUNICH, GERMANY, May 3, 2022 – Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), BioMedPartners, coparion, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners. The new capital will be used to advance Tubulis’ proprietary pipeline of
 
Press
31. March 2022

Improving ARDS treatment with digital twins: Ebenbuild secures seed financing round led by Bayern Kapital and High-Tech Gründerfonds

Munich/Bonn/Landshut, 31 March 2022 – Software start-up Ebenbuild has secured seven-figure funding as part of a seed financing round. Alongside lead investors High-Tech Gründerfonds and Bayern Kapital, the venture and growth capital organisation of the state of Bavaria, a number of well-known business angels also invested in the Munich-based HealthTech start-up, with the funding amounting to €2.5 million. Ebenbuild develops personalised lung simulation models based on patient data. These
 
Press
17. February 2022

Biograil Secures Seed 2 Funding for Oral Delivery Device for Biologics

COPENHAGEN, DENMARK, Jan 17th, 2022 – Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of biologics that would otherwise be injected, announced the closing of a Seed 2 funding of 3.2 million Euro. The Round was led by Danish Megatrend Invest a/s with strong support from other prior investors including Verve Ventures, a Swiss Investment group and Sanner Ventures, a German family office. Evonik Venture Capital participated as a new investor. Ev
 
Press
15. February 2022

Very Successful Exit for High-Tech Gründerfonds – Kerry acquires c-LEcta

This strategically compelling combination will accelerate Kerry’s innovation capabilities in enzyme engineering, fermentation and bio-process developmentThe global presence of Kerry Group plc in the food and pharmaceutical sectors givesc-LEcta access to additional marketsHigh-Tech Gründerfonds was the first seed investor of c-LEcta High-Tech Gründerfonds (“HTGF”) sells its shares in c-LEcta after accompanying the company for 16 years. Kerry Group plc (“Kerry”), the global
 
Press
9. February 2022

Lindis Blood Care successfully closes follow-on financing round 

Funding round supported by High-Tech Gründerfonds (HTGF), Brandenburg Kapital and several private investors, showing their continued commitmentFunds to be mainly used to complete ongoing REMOVE study with CATUVAB®, extend clinical program, complete CE marking procedure, start FDA market application process and support partnering activitiesCATUVAB® is a novel approach designed to be a safe and cost-effective way to reliably remove tumor cells from autologous blood Hennigsdorf, Germa
 
Blog
18. May 2022

GWA Hygiene and Dräger: From collaboration to investment

How does a company specialized in medical and safety technology with a more than 130-year history end up getting together with a six-year-old start-up? Common goals, collaboration on an equal footing and good partners are key aspects in this regard. That is at least according to Jens Altmann, President Business Unit Data Business at Dräger, and Tobias Gebhardt, CEO at GWA Hygiene. Dräger, a global corporation, recently invested in High-Tech Gründerfonds (HTGF) portfolio company GWA Hygien